Restoring value to stalled Phase II compounds: the case for developing a novel compound for depression using pharmacogenetics

  • Carol Reed, , Matthew Kalnik, , Kevin Rakin, Maria Athanasiou, Richard Judson
  • Pharmacogenomics, March 2005, Future Medicine
  • DOI: 10.1517/14622416.6.2.95

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr Richard S Judson

join the fight against climate change

Our simple summaries of climate research help you take action

Read now